J&J’s Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront

Kyle LaHucik

Senior Reporter

Johnson & Johnson’s Janssen unit is delving into the muscarinic space with $50 million upfront for an oral Pipeline Therapeutics asset that will enter a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J’s Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sana narrows focus again to zero in on diabetes and autoimmune disease

Vertex makes money from sickle cell therapy Casgevy

The election is Tuesday. What’s at stake for the pharma industry?

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

J&J’s Janssen taps in­to Pipeline Ther­a­peu­tics’ neu­ro­science as­set for $50M up­front

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

Is there room for MASH drugs in a GLP-1 world?

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

J&J’s Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sana narrows focus again to zero in on diabetes and autoimmune disease

Vertex makes money from sickle cell therapy Casgevy

The election is Tuesday. What’s at stake for the pharma industry?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks